Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer
Open accessThe DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Abstract
Immune checkpoint blockade (ICB) has a limited effect on colorectal cancer, underlining the requirement of co‐targeting the complementary mechanisms. Here, we identified prostaglandin E2 (PGE 2 ) receptor 4 (EP4) as the master regulator of immunosuppressive myeloid cells (IMCs), which are the major driver of resistance to ICB therapy. PGE 2 ‐bound EP4 promotes the differentiation of immunosuppressive M2 macrophages and myeloid‐derived suppressor cells (MDSCs) and reduces the expansion of immunostimulated M1 macrophages. To explore the immunotherapeutic role of EP4 signaling, we developed a novel and selective EP4 antagonist TP‐16. TP‐16 effectively blocked the function of IMCs and enhanced cytotoxic T‐cell‐mediated tumor elimination in vivo . Cell co‐culture experiments revealed that TP‐16 promoted T‐cell proliferation, which was impaired by tumor‐derived CD11b + myeloid cells. Notably, TP‐16 and anti‐PD‐1 combination therapy significantly impeded tumor progression and prolonged mice survival. We further demonstrated that TP‐16 increased responsiveness to anti‐PD‐1 therapy in an IMC‐related spontaneous colorectal cancer mouse model. In summary, this study demonstrates that inhibition of EP4‐expressing IMCs may offer a potential strategy for enhancing the efficacy of immunotherapy for colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additional preclinical studies showed that repolarizing TAMs enhanced T-cell-mediated anti-tumor immune response and improved the efficacy of ICIs in CRC tumors [234,235].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [234]
In the citing paper
“which enhanced T-cell-mediated anti-tumor immunity and improved the efficacy of anti-PD-1 [58].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [58]
In the citing paper
“TP-16 (EP4 antagonist) treatment polarized TAM from immunosuppressive M2 type to pro-inflammatory M1 type”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [58]
In the citing paper
“Preclinical studies show that prostaglandin E2 (PGE2) receptor 4 (EP4), as the primary regulator of IMC, can mediate drug resistance by promoting the differentiation and proliferation of M2 TAM and MDSC [58].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“In 2018, more than 1.8 million new cases and 881,000 deaths were reported worldwide (Bray et al, 2018).”
BackgroundInfluentialAutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486 · cited 1×
“To investigate the detailed interaction between EP4 and TP-16, in silico molecular docking was performed using AutoDock (Morris et al, 2009).”
MethodSiegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160 · cited 1×
“Colorectal cancer has a high incidence and mortality rate (Siegel et al, 2019).”
BackgroundColorectal cancer statistics, 2020
Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., Cercek, A., Smith, R. A., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21601 · Cited by 4,880 · cited 1×
“The prognosis for patients with distantstage disease is dismal, with a 5-year relative survival rate of only 14% (Siegel et al, 2020).”
BackgroundImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 1×
“For instance, anti-CTLA4 antibody was approved for metastatic melanoma, and anti-PD-(L)1 antibodies were approved for a wide range of cancer types, such as melanoma, lung cancer, and renal carcinoma (Topalian et al, 2015; Patel & Minn, 2018).”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“IMCs mainly comprise tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) (Gabrilovich et al, 2012).”
BackgroundImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057 · cited 1×
“Diverse regulatory mechanisms are exploited by cancer cells to establish a strong immunosuppressive tumor microenvironment that supports tumor growth, fuels tumor immune escape, and weakens immunotherapeutic efficacy (Zou, 2005; Fleming et al, 2018).”
BackgroundThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008 · cited 1×
“A high frequency of MDSCs is generally associated with poor disease progression and therapy resistance in colorectal cancer (Solito et al, 2011; Marvel & Gabrilovich, 2015; Kumar et al, 2016).”
BackgroundImmunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954 · cited 1×
“Immune checkpoint blockade (ICB) has emerged as the standard therapy for many cancers due to its unprecedented and durable responses in patients with refractory cancers (Hoos, 2016; Ganesh et al, 2019).”
BackgroundBöttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857 · cited 1×
“For instance, tumorderived PGE2 drives cancer progression by impairing natural killer cells and the conventional dendritic cell resulting in cancer immune evasion (Zelenay et al, 2015; Bottcher et al, 2018).”
Background
Cited by
The cancer metabolic reprogramming and immune response
Xia, L., Oyang, L., Lin, J., Tan, S., Han, Y., Wu, N., Yi, P., Tang, L., Pan, Q., Rao, S., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01316-8 · Cited by 1,312
Overcoming TGFβ-mediated immune evasion in cancer
Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377
Gong, Z., Li, Q., Shi, J., Wei, J., Li, P., Chang, C.-H., Shultz, L. D., & Ren, G. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.001 · Cited by 239
Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells
Jin, K., Qian, C., Lin, J., & Liu, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1099811 · Cited by 182
“Emerging data from multiple solid tumor mouse models indicates that EP4 antagonists and PD1/PD-L1 blockade are effective in inhibiting primary tumor growth (49, 95, 96).”
BackgroundRegulatory cells and the effect of cancer immunotherapy
Iglesias-Escudero, M., Arias-González, N., & Martínez-Cáceres, E. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01714-0 · Cited by 191
Metadata
- Authors
- Lu, W., Yu, W., He, J., Liu, W., Yang, J., Lin, X., Zhang, Y., Wang, X., Jiang, W., Luo, J., Zhang, Q., Yang, H., Peng, S., Yi, Z., Ren, S., Chen, J., Siwko, S., Nussinov, R., Cheng, F., Zhang, H., & Liu, M.
- Affiliations
- East China Normal University (CN)
- Second Military Medical University (CN)
- Ningxia Medical University (CN)
- Texas A&M University (US)
- Tel Aviv University (IL)
- Cleveland Clinic (US)
- Corresponding author
- Zhang, Hankun
- Liu, Mingyao
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2020-12-07
- Volume
- 13
- Issue
- 1
- Pages
- e12798-e12798
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC7799360
- OpenAlex
- W3112267375
- Cited by
- 112
- References
- 66
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 27 · 2023: 25 · 2022: 21 · 2021: 14 · 2020: 1
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81972828, 81830083, 21977032, 2020ZX09201‐003)
- Shanghai Municipal Education Commission (2017‐01‐07‐00‐05‐E00011)
- Shenzhen (KQTD2017081060226082)
- Shanghai Committee of Science and Technology (18431900500, 19ZR1473500, 18431900100)
- National Key R&D Program of China (2018YFA0507000)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- colorectal cancer, EP4 receptor, prostaglandin E2, immunosuppressive myeloid cells, M2 macrophages, myeloid-derived suppressor cells, EP4 antagonist, immune checkpoint inhibitor resistance, anti-PD-1 combination therapy, T cell proliferation, tumor immunosuppression
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Immunotherapy, Colorectal Neoplasms, Myeloid Cells, Mice, Receptors, Prostaglandin E, EP4 Subtype
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. https://app.cochat.ai/papers/10.15252/emmm.202012798
- The paper
- Lu, W., Yu, W., He, J., Liu, W., Yang, J., Lin, X., Zhang, Y., Wang, X., Jiang, W., Luo, J., Zhang, Q., Yang, H., Peng, S., Yi, Z., Ren, S., Chen, J., Siwko, S., Nussinov, R., Cheng, F., . . . Liu, M. (2021). Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202012798
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.